Abstract
Introduction
Normal pregnancy is associated with enhanced endothelial function and formation of new blood vessels. Regulation of endothelial function requires an interaction between endothelial cells and subpopulations of circulating cells, termed endothelial progenitor cells (EPCs). 1 Since first explained by Asahara et al, 2 the definition of EPCs and techniques used for their assessment have gone through many changes. Hill and coworkers 3 introduced a colony-forming assay [colony forming unit (CFU) -Hill] in the field, and Peichev et al 4 suggested the combination of CD34, CD133, and CD309 as the flow cytometric identifying the phenotype for EPCs. However, more recent data are also persuasive, further suggesting that the two mentioned methods introduce cells that exhibit monocyte characteristics (such as expressing CD14 and CD45) in conjunction with markers from endothelial lineage (such as CD34 and CD309), which are from a hematopoietic hierarchy. These cells do not differentiate into endothelial cells or assemble into vascular networks in vitro, and thus cannot be true EPCs. 5 Eventually, Ingram et al 6 discovered cells with more appropriate characteristics as true EPCs, the so-called endothelial colony-forming cells (ECFCs). Based on that, ECFCs express CD34 and CD309 but lack CD14, CD45, and CD133. 6 Despite these, both CFUHills and circulating EPCs measured by flow cytometry remained under the classification umbrella of EPCs in the literature but they were renamed as CFU-endothelial cells (CFU-ECs) and circulating angiogenic cells (CACs), respectively. 5, 7 Nevertheless, reduced CFU-EC and CAC numbers correlate with increased risk of vascular disease and the strong correlation between their numbers and abnormal function of endothelial cells cannot be ignored. 5 In this regard, only a few studies have been performed regarding the role of EPCs in normal pregnancies and preeclampsia, as an example of gestational vascular disorder, and the results of those studies are highly controversial. 8 This may be due to the variety of surface markers, and functional assays have been used to assess EPC numbers that make the comparison between their results more difficult. Furthermore, all of these studies were cross-sectional and relatively few studies used both flow cytometry and culture techniques to compare EPC subsets. Therefore, using flow cytometry and culturing techniques in a prospective study, we compared the number of all EPC subsets including: CACs, CAC precursors (CD34
À

CD133
þ CD309 þ cells), 9 putative ECFCs, and CFUECs in three trimesters of normal pregnancy and in a caseecontrol study the similar values from patients with preeclampsia were compared with the findings from gestational age-matched normal pregnancies.
Methods
Study population
Nine healthy women in their first trimester of pregnancy were enrolled in this study. The participants were followed-up during their total course of pregnancy from April 2011 to May 2012 and peripheral blood samples were taken sequentially in each trimester. The exclusion criteria consisted of affliction with diabetes mellitus, malignancies, autoimmune disease, hypertension, chest pain induced by physical activities, vascular claudication, current episode of infection, and a family history of premature cardiac events or severe abnormal lipid profiles. Eight pregnant women diagnosed with preeclampsia, defined as the new onset of hypertension (systolic blood pressure ! 140 mmHg and diastolic blood pressure ! 90 mmHg) and proteinurea (! 0.3 g in a 24-hour urine specimen) after 20 weeks of gestation in a previously normotensive woman were recruited in the study. 7 All participants gave their written informed consent before enrolment in this study. This study was approved by the local Ethics Committee and conformed to the Declaration of Helsinki.
Preparation of mononuclear cells
Peripheral blood samples (20 mL) were taken, diluted using 15 mL of phosphate buffered saline (PBS), and brought onto the layer of Lymphosep (Biosera, Boussens, France). They were then centrifuged at 300g continuously for 25 minutes and finally the layer of mononuclear cells (MNCs) was isolated. The total number of isolated cells was determined using hemocytometer and the purified cells were divided into two tubes for the following steps.
CFU-EC assay
Half of the isolated MNCs were resuspended in 4 mL of Endocult medium (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco/Invitrogen, Carlsbad, CA, USA). Two-milliliter aliquots of this suspension was seeded per well of 6-well fibronectin-coated plates (BD Biosciences, San Jose, CA, USA) and incubated for 2 days at 37 C, 5% CO 2 , and 95% humidity. Afterwards, the nonadherent cells were harvested by flushing prewarmed media and replated in 96-well fibronectin-coated plates (BD Biosciences). After 5 days, the culture medium was removed and the plates washed with PBS to remove nonadherent cells. To increase the accuracy, the tests were done in duplicate and the colonies were counted by two independent expert technicians.
Quantitative flow cytometry
Because of the low frequency of the target cells in the peripheral blood, our flow cytometry protocols followed rare cell analysis protocols. 10 Consequently, all the mononuclear cells purified from half of the blood sample (equivalent to 10 mL or at least 10 6 cells) were stained and analyzed through flow cytometry. Propidium iodide and dead cell removal kits (Miltenyi Biotec, Bergisch Gladbach, Germany) were used before the actual staining to exclude dead cells from the harvested cells to decrease the chance of nonspecific cell bindings. 10 The isolated cells were stained with antibodies against CD34-fluorescein isothiocyanate, CD133-phycoerythrin, CD309-allophycocyanin, and CD45-peridinin chlorophyll protein while the cells were treated with Fc receptor blocking reagent (all obtained from Miltenyi Biotec). Cell suspensions were incubated in the dark at 4e8 C and washed twice; the cell pellets were resuspended in 520 mL of PBS-EDTA buffer supplemented with 2% fetal bovine serum. To enumerate cell population of interest, TruCOUNT kit (BD Biosciences) was used. Accordingly, stained cell suspensions were transferred to the TruCOUNT tubes and immediately analyzed by four-color FACS-Calibur instrument (BD Biosciences). Isotype matched antibodies (Miltenyi Biotec) were used to exclude nonspecific staining of the cells in every staining. CellQuest Pro software (BD Biosciences) was used for data acquisition and WinMDI software was used for data analysis and graphical presentation of data. Fig. 1 shows the way that cells were gated for analysis and enumeration of the desired cells. The absolute cell count per mL of blood samples was calculated by the formula provided in the TruCOUNT kit instructions:
À as ECFCs, 6 and CD34
þ CD309 þ cells as CAC precursors. 9 In addition, to cover other reported phenotypes for CACs and ECFCs in the literature, 11 we enumerated 10 other cell populations listed in Tables 1 and 2 . 5,11,17,18,20e23 Fig. 1. Typical dot plot diagrams defining some of the variable regions used to enumerate absolute counts of the circulating angiogenic cells marked as
Number of events in target region Â number of beads in the tube=number of events in bead region Â sample volume:
Statistical analysis
The numbers of 13 distinct cell populations were measured with flowcytometry and those for CFU-EC derived from culturing techniques were calculated in 1 mL of whole blood or in 10 6 purified MNCs to address the controversies in the literature. Eventually, 28 parameters were gathered for comparison between the three trimesters or between preeclampsia with GA-matched normal pregnancies. The number of cells is reported as mean ± standard deviation. Normality of the distribution of continuous data was examined using the KolmogoroveSmirnov test. Logarithmic transformation was Table 1 Enumeration data for 10 putative endothelial progenitor cell populations during three gestational trimesters produced by flow cytometry analysis. 
Results
Samples and participants
In this study, we compared the number of EPC subsets in the peripheral blood samples from nine normal pregnant women and eight patients with preeclampsia. The mean gestational age of the patients with preeclampsia and gestational age matched normal pregnant women were 32.29 weeks and 31.8 weeks, respectively, which were not significantly different ( p ¼ 0.641). Some of the clinical characteristics of the patients with preeclampsia and of healthy pregnancies in subsequent trimesters are shown in Table 3 .
Quantification of EPC subsets
Flow cytometry was used to enumerate CACs, precursors of CAC and putative populations of ECFCs, and culture techniques were used to enumerate the number of CFU-ECs, both in 1 mL of blood and in 10 6 purified MNCs. There were higher numbers of CFU-ECs when comparing per mL of blood during the first trimester of the normal pregnancies (27.8 colonies/mL) than the second and third trimesters with slightly higher numbers in the third trimester compared to the second (16.72 colonies/mL and 24.02 colonies/mL, respectively; Fig. 2A) . Nevertheless, neither of the observed variations during normal pregnancy was significant ( p ¼ 0.322). The number of CFU-ECs when determined in 10 6 MNCs showed no significant change either (Fig. 2B , p ¼ 0.181). The frequency of CACs found in the unit of the peripheral blood was significantly elevated as gestational age increased in normal pregnancies. For example, CAC frequency was 106.25 cells/mL during the first trimester, and increased to 239 cells/mL in the third trimester ( Fig. 2C; p ¼ 0.016) . However, the increase showed no significance when numbers of CACs were calculated among 10 6 MNCs (Fig. 2D,  p ¼ 0.136) . The number of precursors of CACs in 1 mL of blood rose as gestational age increased (Fig. 2E, p < 0.001 ) and again this rise was insignificant when the numbers were calculated among 10 6 MNCs (Fig. 2F, p ¼ 0.019) . Measuring the frequencies of ECFCs by the mentioned phenotypes did not show a significant variation during different trimesters of normal pregnancies (Fig. 2G and H, p ¼ 0.031) . In addition to those populations, the actual frequencies of 10 other cell populations expressing various combinations of surface markers from the peripheral blood of women with normal pregnancy are listed in Table 1 .
We found significantly higher numbers of CFU-EC per mL of blood in the gestational age matched normal pregnant women compared with preeclamptic patients (Fig. 3A, p ¼ 0.039) . When extrapolating the data in 10 6 MNCs, this significance was lost (Fig. 3B, p ¼ 0.078) . The counts of CACs per 1 mL of blood and in 10 6 MNCs had a difference that was not statistically significant ( Fig. 3C and D MNCs was also significantly higher in the preeclampsia group (Fig. 3F, p ¼ 0.029) . The analysis of the ECFC numbers showed no considerable difference between the two studied groups (Fig. 3G and H, p ¼ 0.677) . Absolute numbers from 10 other cell populations expressing various combinations of surface markers in normal and diseased states are shown in Table 2 .
Discussion
In the present study, through flow cytometric studies we could show that higher numbers of CACs and ECFCs subsets Table 3 Clinical profiles of the individuals with normal pregnancy or preeclampsia.
General characteristics of normal pregnancies Maternal age (y)
29.33 ± 4.58 (21e36) Nuliparity (%) 55.6 1 st trimester 2 nd trimester 3 rd trimester Gestational age at the day of sampling (wk) 9.8 ± 1.7 (7e13) 24.7 ± 2.1 (22e27) 33.6 ± 2.6 (31e38) Systolic blood pressure (mmHg) 108.8 ± 9.2 (100e120) 107.6 ± 11.2 (90e120) 106.8 ± 9.2 (90e120) Diastolic blood pressure (mmHg) 67.7 ± 8.3 (60e80) 68.7 ± 7.3 (60e80) 67.9 ± 9.1 (60e80) Urine protein (dipstick) 0þ 0þ 0þ are mobilized in the peripheral blood of pregnant women with preeclampsia compared with normal pregnancies, but with lower colony-forming capacities (shown by CFU-EC assay). By contrast, the number of these cells increases as gestation goes ahead in a healthy pregnancy and their functional capacities remain intact in this setting. The pattern of these changes and their significance is open to comparison of these results with those from previous studies, as discussed below. In this regard, some controversies have been previously reported about the frequency of EPCs in different trimesters of normal pregnancies as well as in preeclampsia. This might be related to several factors. First of all, there is a lack of consensus on the definitive EPC phenotype and a variety of surface markers, and functional assays have been used to enumerate these cells. Besides, the resultant data are reported in two ways: numbers in the volume of blood and frequencies in a defined number of MNCs, which makes the comparison of different clinical studies difficult. Furthermore, some technical issues were not taken into consideration. For example, in flow cytometric studies, Matsubara et al 12 did not perform an absolute count of the cells, while Buemi et al 13 did that only on the CD34 þ population, and none of the studies analyzed a sufficient number of cells as needed in the settings of rare cell analysis. 10 In addition, the absence of a prospective approach, at least in part, could explain some of the existing variations among reported results. Therefore, in this prospective study we analyzed all the EPC subsets by considering the suggested patterns in flow cytometry and culture techniques. Moreover, the counts were determined both by calculating the number of cells in the unit volume of blood and the number of cells in 10 6 purified MNCs. Comparison of these two methods of data calculation showed a significant difference in the final results which is discussed below in comparison with previous studies. Regarding healthy pregnancies, Sugawara et al 14 showed a significant increase in CFU-ECs when calculating the cells among 1.5 Â 10 6 MNCs along the gestation time. By contrast, Savvidou et al 15 reported only minor decreases in CFU-ECs calculated among MNCs with progression of pregnancy. Our finding was more consistent with the results of Savvidou et al, 15 reporting EPCs as CFU-ECs counted among 10 6 MNCs. Similar to our findings, Matsubara et al 12 showed a decrease in CFU-ECs in the unit volume of blood as gestational age increased. However, we could see some increase afterwards during the third trimester. Regarding the number of CACs, our data were in accordance with the report by Buemi et al, 13 which showed an increase in the number of CACs in 1 mL of blood with progress in gestational ages. However, our data contradicted results found by Matsubara et al, 12 who concluded that the frequency of CACs in 10 5 MNCs decreased with gestational age. In our study, the number of CD34 À CD133 þ CD309 þ cells that had been purposed to be precursors of CACs 9 increased significantly as gestational age increased.
Similar to the findings of Sugawara et al 16 and Lin et al, 7 we could also show the presence of reduced CFU-ECs among a defined number of MNCs in patients with preeclampsia compared with the gestational age-matched normal pregnancies. In the same way, we showed a lower frequency of CFU-ECs in 1 mL of blood of patients with preeclampsia although it was in contrast with the findings of Matsubara et al. 12 In our study, consistent with the report by Buemi et al, 13 the number of CACs in 1 mL of blood increased in preeclampsia. However, the calculated numbers in 10 6 purified MNCs were in disagreement with the results reported by Matsubara et al. 12 The number of precursors of CACs was also significantly higher in the preeclampsia group.
In our study, we used a flow cytometric technique to enumerate the possible ECFCs. We found a higher number of all possible combination markers as preeclampsia occurred, although only CD309 þ CD45 À profile reached statistical significance. This is in accordance with the findings in acute myocardial infarction; as endothelial damage occurs, the number of ECFCs rises in the peripheral blood. 17, 18 In regards to the normal pregnancy, we did not find any significant differences in the number of possible ECFCs with changes in gestational age. Here, we dispensed with culturing techniques to enumerate ECFCs because the frequency of these cells in the peripheral blood is very low, and large volumes of blood samples are needed for accurate measurements. So, most of our participants refused to donate such volumes of blood in their pregnancy period. In addition, it is shown that the number of culture-derived ECFCs colonies strongly correlated with the number of CD34 þ CD45 À and CD34 þ CD309 þ flow cytometric enumerated cells and without any correlation to the CD34 þ CD133 þ as marker of CACs. 17, 18 Due to the biological functions of EPCs, the differences between the number of CACs and CFU-ECs in normal pregnancies and those with preeclampsia can be expected. It was shown that EPCs can be mobilized from the bone marrow during stress or endothelial injuries (as it happens in preeclampsia or acute myocardial infarction), which results in an increased number of cells in the peripheral blood. 19 In fact, this can be an attempt to promote re-endothelialization of the damaged vessels. However, the functionality of these cells can be affected by chronic inflammation in vascular disorders.
